US/UK/Canada

Share

Contacts

  • STENOCARE A/S
    Nyholmsvej 4 8930 Randers NØ Danmark
    +45 31 77 00 60
    http://www.stenocare.com

    • Quotes

    “We are closely monitoring the weekly sales across our distribution channels to have products ready for patients at all the Danish pharmacies. We have heard concerns from politicians, that there might be challenges securing supply for Denmark. With our ongoing market monitoring and import of products – we will be able to meet the entire demand from all Danish patients”.
    Rolf Steno, CCO
    Pick a time period -
    Tags ( Active)

    STENOCARE completes integration of CannGros ApS

    STENOCARE A/SNASDAQ FIRST NORTH GROWTH MARKET, DENMARKTICKER:  STENO STENOCARE A/S (“STENOCARE”) is pleased to announce that the integration of CannGros ApS, acquired in November 2025, has now been successfully completed by the end of June 2026. The integration of CannGros ApS has been completed as planned, with several successful import, repackaging and sales cycles executed, the corporate merger finalized, and process optimisations implemented to reduce both cost and lead time.The acquisition of CannGros ApS was made to strengthen STENOCARE’s position in the Danish medical cannabis

    Interim report first quarter 2026

    STENOCARE A/SNASDAQ FIRST NORTH GROWTH MARKET, DENMARKTICKER: STENOSTENOCARE A/S (“STENOCARE”) today announces its results for the period 01.01.2026 – 31.03.2026. The report, which has not been reviewed by the Company’s auditors, is attached to this release and is also available on https://stenocare.com/investor-relations/ Thomas Skovlund Schnegelsberg, CEO of STENOCARE, comments: ” Stenocare delivered a strong performance in Q1 2026, marked by solid growth in net sales, a positive EBITDA, and increasing traction in Germany. The integration of CannGros has been successfully

    Communiqué from Annual General Meeting

    STENOCARE A/SNASDAQ FIRST NORTH GROWTH MARET, DENMARKTICKER: STENOOn 29 April 2026 annual general meeting of shareholders of STENOCARE A/S, CVR no. 39024705, was held at Lund Elmer Sandager Law Firm, Kalvebod Brygge 39-41, DK-1560 København V with the following agenda: Agenda: 1. Appointment of a chairman of the meeting 2. Report of the chairman of the board of directors 3. Presentation of the audited annual report together with a resolution for its adoption 4. Resolution to appropriate the profit or cover the loss 5. Proposals from the Board of Directors a. Change of

    Notice to Annual General Meeting in STENOCARE A/S

    STENOCARE A/SNasdaq First North Growth Market, DenmarkTicker: STENOThe board of directors hereby convenes the shareholders of STENOCARE to the Annual General Meeting, which will be held: STENOCARE A/S April 29, 2026 at 10:30 AM (CEST) (the doors open at 10:00 AM)                                   at Lund Elmer Sandager Law Firm Kalvebod Brygge 39-41 DK-1560 København V With the following agenda: 1. Appointment of a chairman of the meeting 2. Report of the chairman of the board of directors 3. Presentation of the audited annual report together with a resolution

    STENOCARE A/S publishes Annual Report 2025

    STENOCARE A/SNASDAQ FIRST NORTH GROWTH MARKET, DENMARKTICKER: STENO The Board of Directors and the Chief Executive Officer of STENOCARE A/S (“STENOCARE”) hereby publish the annual report for the fiscal year 2025. The annual report, including the auditor’s report, is available as an attached file and on STENOCARE’s website and Nasdaq First North .Thomas Skovlund Schnegelsberg, CEO of STENOCARE, comments: “The best year ever: Stenocare exceeded expectations in 2025,

    Interim report fourth quarter and Financial Statement Release 2025

    STENOCARE A/SNASDAQ FIRST NORTH GROWTH MARKET, DENMARKTICKER: STENO STENOCARE A/S (“STENOCARE”) today announces its results for the period 01.01.2025 – 31.12.2025. The report, which has not been reviewed by the Company’s auditors, is attached to this release and is also available on https://stenocare.com/investor-relations/Thomas Skovlund Schnegelsberg, CEO of STENOCARE, comments: ” Strong performance in Q4, again - Stenocare exceeded its expectations in 2025, delivering three consecutive quarters of positive EBITDA and continued growth in net sales throughout the year. In

    STENOCARE A/S positions for First-Mover Advantage in France With Strategic Partnership, Product Filing, and National Distribution Partnership

    STENOCARE A/SNASDAQ FIRST NORTH GROWTH MARKET, DENMARKTICKER:  STENO STENOCARE A/S (“STENOCARE”) has entered a strategic partnership with Institut des Cannabinoïdes Médicaux Français (=“ICMF”) to position the Company as a first mover in the emerging French medical cannabis market, which is expected to transition to permanent legalization in 2026. As part of this initiative, STENOCARE and ICMF have submitted a full regulatory dossier for STENOCARE’s innovative ASTRUM 10-10 oil product to the French medical authorities within the national process to evaluate medical cannabis for

    Stenocare Kicks Off Strategic Partnership with WEECO to Launch New Astrum Oil Product in Germany

    STENOCARE A/SNASDAQ FIRST NORTH GROWTH MARKET, DENMARKTICKER:  STENO Stenocare Enters Strategic Partnership with WEECO Pharma GmbH to Launch Premium Medical Cannabis Oils in Germany. The first new product is WEECO ASTRUM 10-10 extract, that will be available for patients during February 2026.Stenocare A/S (“Stenocare”), a European supplier of prescription-based medical cannabis products, today announces a strategic partnership with WEECO Pharma GmbH (“WEECO”), a German pharmaceutical company specializing in cannabinoid-based medicines. This collaboration marks the official launch of

    Trading in STENOCARE shares by closely related party to board member

    STENOCARE A/SNASDAQ FIRST NORTH GROWTH MARKET, DENMARKTICKER:  STENOThis information is information that STENOCARE A/S is obliged to publish in accordance with the EU Market Abuse Regulation. The information was provided by the contact person below for publication on December 30, 2025. This company announcement discloses the data of the transactions made in STENOCARE shares by a closely related party to a board member in accordance with Article 19 of regulations no 596/2014 on market abuse. The company’s board member has reported the transactions to Stenocare A/S.  1 Details of

    STENOCARE share analyst’s comments on the CannGros acquisition

    STENOCARE A/SNASDAQ FIRST NORTH GROWTH MARKET, DENMARKTICKER:  STENO STENOCARE A/S announced November 18 that it had acquired 100% of the shares in CannGros ApS. This press release share additional insight on the value of the acquisition.Stenocare has paid investor relations agreement with Swedish Analyst Group and Danish Proinvestor.com. With this, Stenocare is offering shareholders and investors the opportunity to have deeper insight into the strategy, the execution and the value for the Company. Analyst Group is a research firm focused on small- and micro-cap companies. They

    Correction of total shares issued and total nominal share capital:

    Total number of shares before capital increase has been corrected from 38,195,978 to 38,403,745 and total number of shares after capital increase has been corrected from 43,195,978 to 43,403,745. Total nominal share capital before capital increase has been corrected from DKK 3,055,678.24 to DKK 3,072,299.60 and the nominal share capital after capital increase has been corrected from DKK 3,455,678.24 to DKK 3,472,299.60. STENOCARE A/SNASDAQ FIRST NORTH GROWTH MARKET, DENMARKTICKER:  STENO STENOCARE A/S acquires CannGros ApS and add DKK 4-6 million in annual revenue and supports 2026

    STENOCARE A/S acquires CannGros ApS and add DKK 4-6 million in annual revenue and supports 2026 break even goal

    STENOCARE A/SNASDAQ FIRST NORTH GROWTH MARKET, DENMARKTICKER:  STENO This information is information that STENOCARE A/S is obliged to publish in accordance with the EU Market Abuse Regulation. The information was provided by the contact person below for publication on November 17, 2025. STENOCARE A/S (“Stenocare” or the “Company”) announces that it has entered into a share purchase agreement with DanCann Pharma A/S (“DanCann”) to acquire 100% of the shares in CannGros ApS (“CannGros”), a wholly owned subsidiary of DanCann. With this agreement, Stenocare enters a new product category

    STENOCARE A/S acquires CannGros ApS and add DKK 4-6 million in annual revenue and supports 2026 break even goal

    STENOCARE A/SNASDAQ FIRST NORTH GROWTH MARKET, DENMARKTICKER:  STENO This information is information that STENOCARE A/S is obliged to publish in accordance with the EU Market Abuse Regulation. The information was provided by the contact person below for publication on November 17, 2025. STENOCARE A/S (“Stenocare” or the “Company”) announces that it has entered into a share purchase agreement with DanCann Pharma A/S (“DanCann”) to acquire 100% of the shares in CannGros ApS (“CannGros”), a wholly owned subsidiary of DanCann. With this agreement, Stenocare enters a new product category

    Interim report third quarter 2025

    STENOCARE A/SNASDAQ FIRST NORTH GROWTH MARKET, DENMARKTICKER: STENO STENOCARE A/S (“STENOCARE”) today announces its results for the period 01.01.2025 – 30.09.2025. The report, which has not been reviewed by the Company’s auditors, is attached to this release and is also available on https://stenocare.com/investor-relations/Thomas Skovlund Schnegelsberg, CEO of STENOCARE, comments: ” Stenocare continues to see the strong results of its STENOCARE 3.0 strategy, delivering the best quarter in the company’s history since 2019. In Q3 2025, we achieved both increased sales and positive

    Trading in STENOCARE shares by closely related party to board member

    STENOCARE A/SNASDAQ FIRST NORTH GROWTH MARKET, DENMARKTICKER:  STENOThis information is information that STENOCARE A/S is obliged to publish in accordance with the EU Market Abuse Regulation. The information was provided by the contact person below for publication on August 27, 2025. This company announcement discloses the data of the transactions made in STENOCARE shares by a closely related party to a board member in accordance with Article 19 of regulations no 596/2014 on market abuse. The company’s board member has reported the transactions to Stenocare A/S. 1 Details of the

    Interim report second quarter 2025

    STENOCARE A/SNASDAQ FIRST NORTH GROWTH MARKET, DENMARKTICKER: STENO STENOCARE A/S (“STENOCARE”) today announces its results for the period 01.01.2025 – 30.06.2025. The report, which has not been reviewed by the Company’s auditors, is attached to this release and is also available on https://stenocare.com/investor-relations/Thomas Skovlund Schnegelsberg, CEO of STENOCARE, comments: ”Break-even for a quarter the first time since 2019. Stenocare is beginning to see the benefits of its STENOCARE 3.0 strategy, with increasing sales and a positive EBITDA. The Q2 report shows momentum

    Communiqué from the Annual General Meeting of STENOCARE

    STENOCARE A/SNASDAQ FIRST NORTH GROWTH MARKET, DENMARKTICKER:  STENOAnnual general meeting On 15 May 2025 annual general meeting of shareholders of STENOCARE A/S, CVR no. 39024705, was held at Lund Elmer Sandager Law Firm, Kalvebod Brygge 39-41, DK-1560 København V with the following agenda: Agenda: 1. Appointment of a chairman of the meeting 2. Report of the chairman of the board of directors 3. Presentation of the annual report together with a resolution for its adoption 4. Resolution to appropriate the profit or cover the loss 5. Election of members of the board of

    Interim report first quarter 2025

    STENOCARE A/SNASDAQ FIRST NORTH GROWTH MARKET, DENMARKTICKER: STENO STENOCARE A/S (“STENOCARE”) today announces its results for the period 01.01.2025 – 31.03.2025. The report, which has not been reviewed by the Company’s auditors, is attached to this release and is also available on https://stenocare.com/investor-relations/Thomas Skovlund Schnegelsberg, CEO of STENOCARE, comments: ” The Company has truly entered the new STENOCARE 3.0 phase, built around a strong trading platform, high-quality products, and sufficient liquidity to execute our growth strategy.” [](KDKK) 01.

    Medical Cannabis Made Permanent in Denmark: Major Milestone for Patients and STENOCARE

    STENOCARE A/SNASDAQ FIRST NORTH GROWTH MARKET, DENMARKTICKER:  STENO STENOCARE A/S (“Stenocare”) is pleased to announce that the Danish Parliament has officially passed legislation to make Denmark’s medical cannabis program permanent. The new law, which takes effect on January 1, 2026, marks a significant step forward in securing long-term access to medical cannabis treatment for patients and providing regulatory stability for the Stenocare business in Denmark.Since 2018, Denmark has operated a Pilot Programme for medical cannabis, which is scheduled to expire in December 2025.

    Notice to Annual General Meeting in STENOCARE A/S

    STENOCARE A/SNasdaq First North Growth Market, DenmarkTicker: STENOThe board of directors hereby convenes the shareholders of STENOCARE to the Annual General Meeting, which will be held: STENOCARE A/S 15 May 2025 at 10:00 AM (CEST) (the doors open at 9:30 AM)                                   at Lund Elmer Sandager Law Firm Kalvebod Brygge 39-41 DK-1560 København V With the following agenda: 1. Appointment of a chairman of the meeting 2. Report of the chairman of the board of directors 3. Presentation of the audited annual report together with a resolution for

    STENOCARE ASTRUM 10-10 Oil Product Approved for Reimbursement in Germany

    STENOCARE A/SNASDAQ FIRST NORTH GROWTH MARKET, DENMARKTICKER:  STENO STENOCARE A/S (“Stenocare”) and its local partner have successfully secured approval for the reimbursement of the innovative ASTRUM 10-10 product by major German health insurance providers. Starting in April 2025, approximately 14 million insured individuals will be eligible for 100% reimbursement when treated with ASTRUM 10-10.The ASTRUM 10-10 oil product was made available to German patients in January 2025 and has now been approved for 100% reimbursement by two leading German health insurance providers, Techniker

    STENOCARE Begins Sales of New CBD100 Oil Product in Denmark

    STENOCARE A/SNASDAQ FIRST NORTH GROWTH MARKET, DENMARKTICKER:  STENO STENOCARE A/S (“Stenocare”) has delivered the first shipment of its new CBD100 Oil product to the Danish market. With this new medical cannabis oil product, Stenocare now offers four different prescription-based medical cannabis oil products to Danish patients, making it the leading provider of oil products in the Danish Pilot ProgrammeSince 2018, Stenocare has been a leading supplier of prescription-based medical cannabis oil products in the Danish Pilot Programme. The company already offers a THC30 Oil product, a

    STENOCARE interview with Proinvestor.com – Annual Report 2024

    STENOCARE A/SNASDAQ FIRST NORTH GROWTH MARKET, DENMARKTICKER:  STENO STENOCARE A/S (“Stenocare”) participated in a video-recorded interview with Proinvestor.com to discuss the Annual Report for 2024. The Stenocare CEO and CFO are answering questions from Proinvestor Editor, Helge Larsen.Stenocare published the Annual Report 2024 on March 27 which is available on the company investor page. The Stenocare CEO and CFO both participated in an interview with Proinvestor.com to comments on the results, the new STENOCARE 3.0 strategy and the capital raise that all had an impact on the

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Media